Kiniksa Pharmaceuticals, Ltd. KNSA 深 沪
等待开盘 07-17 09:30:00 美东时间
28.42
+0.330
+1.17%
华盛通- 最 高28.96
- 今 开28.38
- 成交量 33.97万股
- 最 低 28.30
- 昨 收 28.09
- 总市值 20.74亿
- 52周最高 30.69
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 17.82
- 委 比 -93.25%
- 总股本 7297.10万
- 历史最高 32.88
- 量 比 0.70
- 振 幅 2.35%
- 历史最低 5.01
- 每 手 1
- 风险率 3.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $42
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $30 to $42.
07-09 21:14
Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans
The latest update is out from Kiniksa Pharmaceuticals ( ($KNSA) ). On June 5, 2...
06-05 19:28
Kiniksa Pharma Announces Details For Planned Phase 2/3 Clinical Trial Of KPL-387 In Recurrent Pericarditis, Expected To Initiate In Middle Of 2025
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and webcast at Jefferies 2025
06-05 19:07
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
Kiniksa Pharmaceuticals announced that its Phase 2/3 trial for KPL-387 in recurrent pericarditis is set to begin in mid-2025, with Phase 2 data anticipated in late 2026. KPL-387, a monoclonal antibody targeting IL-1R1, shows potential for monthly subcutaneous dosing. The trial design is supported by Phase 1 data, and management highlighted its commitment to advancing KPL-387. A presentation on KPL-387's progress was held at the Jefferies 2025 Glo...
06-05 11:00
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions
Kiniksa Pharmaceuticals ( ($KNSA) ) has issued an announcement. On June 3, 2025...
06-04 05:04
Small-caps showing signs of potential breakout – BTIG
The Russell 2000 Index (NYSEARCA:IWM) is attempting to break out of a seven-month downtrend, potentially signaling a significant shift in market dynamics, according to Jonathan Krinsky, chief market t...
06-04 01:54
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced that its management will present at two upcoming investor conferences in June: the Jefferies 2025 Global Healthcare Conference on June 5 at 12:50 p.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 8:00 a.m. ET. Presentations will be webcast live and available for replay on the Investors & Media section of the company’s website, www.kiniksa.com. K...
05-29 20:01
Kiniksa Pharmaceuticals Q1 2025 Earnings: Strong Growth
Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q1 earnings call. R...
05-01 08:55
美股牛股 | 与诺和诺德达成合作！LifeMD飙升41%，HIMS大涨23%
与诺和诺德达成合作！LifeMD飙升41%，HIMS大涨23%；禾赛大涨18%，与可庭科技在智能庭院机器人领域展开深度合作>>
04-30 19:00
Kiniksa Pharmaceuticals Raises FY2025 Sales Guidance from $560.00M-$580.00M to $590.00M-$605.00M vs $698.99M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2025 sales outlook from $560.00 million-$580.00 million to $590.00 million-$605.00 million vs $698.99 million estimate.
04-29 19:33
